BIVI Announces 2016 Swine Research Award Recipients

The Respiratory Disease Research Board, with support from Boehringer Ingelheim Vetmedica, Inc. (BIVI), has selected three research proposals to fund as part of its 2016 Awards for Advancing Research in Respiratory Disease program. These research proposals are funded at $35,000 each.

 Formerly known as the PRRS Research Awards, the name was updated in 2016 to  include research projects addressing some of the industry’s most pressing questions about the control and management of PRDC, specifically porcine circovirus Type 2 (PCV2), Mycoplasma hyopneumoniae and influenza A virus in swine (IAV-S), in addition to PRRS. This is the first time in the board’s history that projects covering diseases beyond PRRS were considered.

 “We recognize there are a host of respiratory disease challenges that impact swine production and performance,” says Dr. Daryl Olsen, AMVC veterinarian and member of the Respiratory Disease Research Board. “The board had a tough task of reviewing and selecting three research projects to fund from a total of 20 submitted proposals.

” The Research Award recipients are selected from a board of eight independent swine veterinarians and researchers. BIVI congratulates the 2016 Awards for Advancing Research in Respiratory Disease recipients for the following projects:

• Dr. Mike Murtaugh, Ph.D., University of Minnesota, St. Paul, MN

      o “Pen-Side Respiratory Pathogen Identification”

• Dr. Daniel Linhares, DVM, MBA, Ph.D., Iowa State University, Ames, IA

      o “Herd sensitivity of PRRSv-monitoring schemes on sow herds undergoingvirus elimination”

• Dr. Luis Ochoa, MS, Ph.D., Carthage Innovative Swine Solutions, Carthage,Illinois

      o “Determining the effects of PCV2 viremia qPCR status of piglets at birth on the response to PCV2 vaccine (CircoFLEX®) and subsequent viremia levels and overall growth rate, mortality and culls”

Over the last 12 years, Research Awards totaling $1 million have supported research leading to additional diagnostic testing and sampling processes, identified more effective biosecurity practices, sought to better understand reproductive diseases, and developed risk assessment tools, therapeutic intervention programs and vaccination strategies. The program is supported through funding from BIVI.

 “PRRS and other swine respiratory diseases are high-risk, potentially very costly challenges that swine producers must be able to manage,” says Dr. Reid Philips, technical manager, BIVI. “We are proud to support field-applicable research that gives back to the industry

.” Applications for the 2017 Research Awards will be open in late 2016. For more  information on the Respiratory Disease Research Board  and the Awards for Advancing Research in Respiratory Disease program, visit www.SwineResearchAwards.com.

About the Respiratory Disease Research Board
The Respiratory Disease Research Board, an independent group of swine veterinarians and researchers, selects the Awards for Advancing Research in Respiratory Disease annually. Board members for the 2016 award selection process include:

1. • Luc Dufresne, DVM, Seaboard Foods, Shawnee Mission, Kansas
2. • Tim Loula, DVM, Swine Vet Center, P.A., St. Peter, Minnesota
3. • Daryl Olsen, DVM, AMVC, Audubon, Iowa
4. • Montse Torremorell, DVM, Ph.D., University of Minnesota, St. Paul
5. • Bill Mengeling, DVM, Ph.D., Diplo. ACVM. Iowa State University, Ames (retired)
6. • Darin Madson, DVM, Ph.D., Diplo. ACVP, Iowa State University, Ames
7. • AASV President (George Charbonneau)
8. • AASV Young Swine Veterinarian of the Year (Aaron Lower)

About Boehringer Ingelheim Vetmedica, Inc.
Boehringer Ingelheim Vetmedica, Inc., (BIVI) is the fifth largest animal health company in the U.S. and produces innovative vaccine and pharmaceutical products for the prevention and treatment of diseases in the swine, cattle, equine and companion animal markets. BIVI is the U.S. subsidiary of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other locations in Ames, Fort Dodge and Sioux Center, Iowa.

With more than 3,600 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about 1.13 billion euros in 2014. In our research-driven Anima Health business, Boehringer Ingelheim continually invests more than 11% of net sales of the Animal Health business in R&D. 

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutica companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In  everything it does, the company focuses on environmental protection and sustainability

Source: Boehringer Ingelheim